Literature DB >> 2979214

Acid secretory capacity and plasma gastrin concentration after administration of omeprazole to normal subjects.

B Sharma1, M Axelson, R P Pounder, P Lundborg, M Ohman, A Santana, M Talbot, C Cederberg.   

Abstract

In a randomized double-blind study, two groups of eight healthy volunteers received either placebo or omeprazole 40 mg o.m. for 14 days. Fasting plasma gastrin concentration and peak acid output in response to a maximal intravenous dose of pentagastrin were measured before, during and after the 14 days of treatment. Omeprazole caused a 68% (mean) decrease in the peak acid output when measured 24 hours after the last dose, with a simultaneous increase in the fasting plasma gastrin concentration. When measured 1, 2, 3 and 8 weeks after cessation of treatment, there was no significant difference in the peak acid output between the two groups. The study demonstrates that there is no increase in the acid production capacity after 2 weeks of treatment with omeprazole. Thus it would appear that the rise in the plasma gastrin concentration during short-term treatment with omeprazole does not induce parietal cell hypertrophy or hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2979214     DOI: 10.1111/j.1365-2036.1987.tb00608.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  8 in total

1.  Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.

Authors:  C U Nwokolo; J T Smith; A M Sawyerr; R E Pounder
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

2.  Double-blind comparison of lansoprazole 15 mg, lansoprazole 30 mg, and placebo in the maintenance of healed gastric ulcer.

Authors:  T O Kovacs; D Campbell; M Haber; P Rose; D E Jennings; J Richter
Journal:  Dig Dis Sci       Date:  1998-04       Impact factor: 3.199

3.  Omeprazole produces parietal cell hypertrophy and hyperplasia in humans.

Authors:  D K Driman; C Wright; G Tougas; R H Riddell
Journal:  Dig Dis Sci       Date:  1996-10       Impact factor: 3.199

4.  Serum pepsinogens after interruption of long-term maintenance therapy with omeprazole in patients with reflux esophagitis.

Authors:  I Biemond; E C Klinkenberg-Knol; C B Lamers; S G Meuwissen
Journal:  Dig Dis Sci       Date:  1993-05       Impact factor: 3.199

Review 5.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 6.  Omeprazole. Overview and opinion.

Authors:  S Holt; C W Howden
Journal:  Dig Dis Sci       Date:  1991-04       Impact factor: 3.199

Review 7.  Effects of hypochlorhydria and hypergastrinemia on structure and function of gastrointestinal cells. A review and analysis.

Authors:  J W Freston; K Borch; S J Brand; E Carlsson; W Creutzfeldt; R Håkanson; L Olbe; E Solcia; J H Walsh; M M Wolfe
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 8.  Omeprazole. Gastrin and gastric endocrine cell data from clinical studies.

Authors:  R G Berlin
Journal:  Dig Dis Sci       Date:  1991-02       Impact factor: 3.199

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.